Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Multiple Myeloma
100%
Overall Survival
87%
Autologous Stem Cell Transplantation
55%
Prognostic Factor
50%
Diffuse Large B-Cell Lymphoma
49%
Progression Free Survival
43%
Bortezomib
35%
Myelodysplastic Syndrome
26%
Acute Myeloid Leukemia
26%
Venous Thromboembolism
25%
Thalidomide
24%
Imatinib
22%
Dexamethasone
20%
Myeloma
20%
Doxorubicin
19%
Clinical Feature
19%
Idiopathic Thrombocytopenic Purpura
19%
Rituximab
18%
Melphalan
17%
Stem Cell Therapy
17%
Chronic Myelogenous Leukemia
17%
Malignant Neoplasm
17%
Cyclophosphamide
16%
NK T Cell Lymphoma
15%
Busulfan
15%
Lactate Dehydrogenase
15%
Observational Study
14%
Survival Rate
14%
Recurrence Free Survival
13%
International Prognostic Index
13%
Vincristine
12%
Paroxysmal Nocturnal Hemoglobinuria
12%
Acute Lymphoblastic Leukemia
12%
Myeloproliferative Neoplasm
12%
Median Follow Up
12%
Thromboembolism
12%
Hematopoietic Stem Cell Transplantation
12%
Multivariate Analysis
12%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Non-Hodgkin Lymphoma
11%
Elderly Patient
11%
Adverse Event
11%
Prednisone
11%
Platelet
10%
Treatment Outcome
10%
Hematopoietic Cell
10%
Predictive Factor
9%
Cord Blood
9%
Thrombosis
9%
Decitabine
9%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
82%
Overall Survival
52%
Chemotherapy Regimens
34%
Bortezomib
32%
Thalidomide
30%
Diffuse Large B Cell Lymphoma
28%
Rituximab
28%
Imatinib
28%
Dexamethasone
27%
Cyclophosphamide
26%
Progression Free Survival
23%
Myelodysplastic Syndrome
22%
Busulfan
22%
Venous Thromboembolism
22%
Lenalidomide
20%
Doxorubicin
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Malignant Neoplasm
17%
Chronic Myeloid Leukemia
16%
Melphalan
15%
Acute Lymphoblastic Leukemia
15%
Febrile Neutropenia
14%
Survival Rate
13%
Decitabine
12%
Antifungal Therapy
12%
Itraconazole
12%
Recurrence Free Survival
12%
Thromboembolism
12%
Clinical Feature
11%
Observational Study
11%
Prednisone
10%
Vincristine
10%
Adverse Event
10%
Remission
10%
Azacitidine
9%
Myeloid Leukemia
9%
Pomalidomide
9%
Radotinib
9%
Reactive Oxygen Metabolite
9%
Fludarabine
9%
Thrombocythemia
9%
Myeloma
9%
Disease Course
8%
Anticoagulant Agent
7%
Frailty
7%
Fluorouracil
7%
Hydroxycarbamide
7%
Hematologic Malignancy
7%
Thrombosis
6%
Paroxysmal Nocturnal Hemoglobinuria
6%
Biochemistry, Genetics and Molecular Biology
Myeloid
64%
Single-Nucleotide Polymorphism
61%
Karyotyping
42%
Overall Survival
38%
Cytogenetics
34%
Metaphase
31%
Single Nucleotide Polymorphism
25%
Fluorescence in Situ Hybridization
21%
Genotyping
19%
Karyotype
18%
Loss of Heterozygosity
17%
Core Binding Factor
15%
Imatinib
15%
Dexamethasone
13%
Decitabine
12%
Event Free Survival
11%
Chromosomal Abnormalities
11%
Interphase
10%
B Cell
8%
Platelet Count
8%
RUNX1T1
7%
RUNX1
7%
Polymorphonuclear Cell
7%
Chromosome 20q
7%
CD34
7%
Lactate Dehydrogenase
7%
Chromosome 7
7%
Chromosome 5
7%
High Risk Population
6%
Progression Free Survival
6%
Clonal Evolution
6%
Azacitidine
6%
CD44
6%
ERCC1
6%
Precursor
6%
Human Leukocyte Antigen
6%
Chromosome 13
6%
Monosomy
6%
Philadelphia Chromosome
6%
Ring Chromosome
6%
Messenger RNA
6%
DNA Repair
5%
Chromosome Analysis
5%
Exon
5%